<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879045</url>
  </required_header>
  <id_info>
    <org_study_id>SHCMIHH2016001</org_study_id>
    <nct_id>NCT02879045</nct_id>
  </id_info>
  <brief_title>Comparison of 2 Body Oil in Prevention of Striae Gravidarum</brief_title>
  <official_title>The Effect of Elasticity Belly® Oil and Clarins® Tonic Body Treatment Oil in Prevention of Striae Gravidarum: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changning Maternity &amp; Infant Health Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changning Maternity &amp; Infant Health Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of elasticity Belly® oil and Clarins® Tonic Body Treatment Oil in prevention of&#xD;
      striae gravidarum: A randomized controlled clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To compare the clinical efficacy of Elasticity Belly® oil and Clarins® Tonic Body&#xD;
      Treatment Oil on the occurrence and severity of striae gravidarum.&#xD;
&#xD;
      Design: Parallel randomized controlled clinical trial. Setting: Gynaecology and Obstetrics&#xD;
      department, Shanghai Changning Maternity and Infant Health Hospital, China Interventions: We&#xD;
      will enroll about 50 Nulliparous women randomly, who are in their second trimester of&#xD;
      pregnancy. Volunteer's abdomen skin are divided into two parts through medioventral line,&#xD;
      half of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum,&#xD;
      and the other side will use the Clarins® Tonic Body Treatment Oil. Volunteers apply these two&#xD;
      kinds of oil daily until gestational age of 38-40 weeks. We'll take abdomen pictures before&#xD;
      and after interventions, and the occurrence of striae on abdominal skin and its severity will&#xD;
      be evaluated as our primary outcome of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence and severity of striae gravidarum</measure>
    <time_frame>second trimester to term birth</time_frame>
    <description>volunteer's abdomen skin are divided into two parts through medioventral line, half of the abdomen skin will receive the elasticity Belly® oil , and the other side will use the Clarins® Tonic Body Treatment Oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prevention Harmful Effects</condition>
  <arm_group>
    <arm_group_label>elasticity Belly® oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elasticity Belly® oil</intervention_name>
    <description>We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.</description>
    <arm_group_label>elasticity Belly® oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  nulliparous females&#xD;
&#xD;
          -  gestational age of 14-20 weeks&#xD;
&#xD;
          -  20 to 35 years old&#xD;
&#xD;
          -  body mass index (BMI) from 18.5 to 25&#xD;
&#xD;
          -  Clear consciousness, intelligence is normal,stable vital signs&#xD;
&#xD;
          -  Voluntary participation, and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to skin care products&#xD;
&#xD;
          -  twin pregnancies or polypregnancies&#xD;
&#xD;
          -  polyhydramnios&#xD;
&#xD;
          -  miscarriages&#xD;
&#xD;
          -  development of a skin disease&#xD;
&#xD;
          -  corticosteroid usage&#xD;
&#xD;
          -  application of any other cream on the abdominal skin&#xD;
&#xD;
          -  did not received allocated intervention&#xD;
&#xD;
          -  drop out or lost to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shating Lei, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Zhao, M.D.</last_name>
    <phone>13636446556</phone>
    <email>877088319@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shating Lei, PhD</last_name>
    <phone>18801930362</phone>
    <email>leishating@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Changning Maternity &amp; Infant Health Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Zhao, M.D.</last_name>
      <phone>13636446556</phone>
      <email>877088319@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Ling Yang, M.D.</last_name>
      <phone>13611960176</phone>
      <email>kt130@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ling Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>August 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changning Maternity &amp; Infant Health Hospital</investigator_affiliation>
    <investigator_full_name>Ling Yang</investigator_full_name>
    <investigator_title>associal professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

